The FDA has already approved biosimilar versions of Herceptin from Celltrion, Samsung Bioepis and Mylan.
Herceptin is one of Roche’s top-selling drugs, bringing in about $6.93 billion in sales in 2018.
However, sales have been hit by increased biosimilar competition, according to the report.
More articles on pharmacy:
Bristol-Myers urges shareholders to support Celgene takeover
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Martin Shkreli reportedly running his pharma company from prison
